
|Articles|January 21, 2009
AMD drug collaboration
MacuCLEAR and Mystic Pharmaceuticals are to collaborate on MacuCLEAR's upcoming Phase I/II trials of MC 1101 for the treatment and prevention of progression of dry age-related macular degeneration (AMD).
Advertisement
MacuCLEAR and Mystic Pharmaceuticals are to collaborate on MacuCLEAR’s upcoming Phase I/II trials of MC 1101 for the treatment and prevention of progression of dry age-related macular degeneration (AMD).
Mystic Pharmaceuticals produces the VeriDoser targeted, individual-use eyedropper drug delivery system, which MacuCLEAR will use as a platform to deliver doses of MC 1101.
MC 1101, which performed well in preclinical tests, has received FDA Fast Track status, allowing acceleration through the trial and approval process.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
2026 Nobel Prize in Physiology or Medicine awarded for optogenetics discovery
2
Oku Digital Health launches from Topcon to link eye care, primary care
3
EURETINA 2026: Optogenetic therapy MCO-010 aims to restore vision in advanced macular disease
4
Real-world VOYAGER data on faricimab in nAMD, DME, RVO at EURETINA 2026
5



















